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ABSTRACT
Objectives: Evaluating the variation in the strength of
the effect across studies is a key feature of meta-
analyses. This variability is reflected by measures like
τ2 or I2, but their clinical interpretation is not
straightforward. A prediction interval is less
complicated: it presents the expected range of true
effects in similar studies. We aimed to show the
advantages of having the prediction interval routinely
reported in meta-analyses.
Design: We show how the prediction interval can help
understand the uncertainty about whether an
intervention works or not. To evaluate the implications
of using this interval to interpret the results, we
selected the first meta-analysis per intervention review
of the Cochrane Database of Systematic Reviews
Issues 2009–2013 with a dichotomous (n=2009) or
continuous (n=1254) outcome, and generated 95%
prediction intervals for them.
Results: In 72.4% of 479 statistically significant
(random-effects p<0.05) meta-analyses in the Cochrane
Database 2009–2013 with heterogeneity (I2>0), the
95% prediction interval suggested that the intervention
effect could be null or even be in the opposite direction.
In 20.3% of those 479 meta-analyses, the prediction
interval showed that the effect could be completely
opposite to the point estimate of the meta-analysis.
We demonstrate also how the prediction interval can be
used to calculate the probability that a new trial will
show a negative effect and to improve the calculations
of the power of a new trial.
Conclusions: The prediction interval reflects the
variation in treatment effects over different settings,
including what effect is to be expected in future patients,
such as the patients that a clinician is interested to treat.
Prediction intervals should be routinely reported to
allow more informative inferences in meta-analyses.
INTRODUCTION
Interventions may have heterogeneous
effects across studies because of differences
in study populations, interventions, follow-up
length or other factors like publication bias.1
Nevertheless, the usual reporting of a meta-
analysis is focused on the summary effect size
combined with a CI and p value. Typically
also some measure of the between-study het-
erogeneity is presented such as τ2 or the
inconsistency measure I2.2 3 However, neither
of these two metrics can readily point to the
clinical implications of the observed hetero-
geneity. Our objective in the current article
is to show the potential advantages of obtain-
ing and reporting the prediction interval
routinely in meta-analyses because its clinical
meaning is much more straightforward. The
prediction interval presents the heterogen-
eity in the same metric as the original effect
size measure, in contrast to τ2 or I2.
Reporting a prediction interval in addition
to the summary estimate and CI will illustrate
which range of true effects can be expected
in future settings. We describe its merits and
provide working examples to show how it can
be calculated.
Strengths and limitations of this study
▪ In many meta-analyses, there is large variation in
the strength of the effect.
▪ The prediction interval helps in the clinical inter-
pretation of the heterogeneity by estimating what
true treatment effects can be expected in future
settings.
▪ In case of heterogeneity, prediction intervals will
show a wider range of expected treatment effects
than CIs, and thus may lead to different conclu-
sions. This occurred in over 70% of statistically
significant meta-analyses with heterogeneity of
the Cochrane Database of Systematic Reviews.
Completely opposite effects were not excluded in
over 20% of those meta-analyses.
▪ Prediction intervals should be routinely reported
to allow more informative inferences in
meta-analyses.
▪ Limitations are that the calculations and infer-
ences for the prediction interval are based on the
normality assumption, which is difficult to
ensure. Further, the interval will be imprecise if
the estimates of the summary effect and the
between-study heterogeneity are imprecise, for
example, if they are based on only a few, small
studies. Inferences based on the prediction inter-
val are only valid for settings that are similar
(exchangeable) to those on which the
meta-analysis is based.
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METHODS
Interpretation of heterogeneity
Between-study variation in the magnitude of treatment
effects cannot be neglected. One of the main merits of
a meta-analysis may even be that it reveals the variation
of effects in different studies.4 Therefore, summarising
the ﬁndings of a meta-analysis in a single summary value
sacriﬁces potentially informative variation.5 However, the
information that can be directly retrieved from τ2 and I2
with respect to the variation in the effects is limited. The
clinical interpretation of I2 is ambiguous: a high I2 does
not necessarily imply that the study effects are dispersed
over a wide range6 and a low I2 might correspond to
high dispersion,7 because I2 depends on sample size of
the included studies.8 With very large (highly precise)
studies, even tiny differences in effect size may result in
a high I2, while with small (imprecise) studies, very dif-
ferent treatment effects can yield an I2 of 0. Dispersion
in treatment effects is better reﬂected by τ because τ is
the SD of the between-study effects. One could, for
example, estimate the ratio of the effect size over τ,
which can convey how many times larger the treatment
effect is compared with the SD of the effect across
studies.9 But this may still be not very intuitive to a clin-
ical reader. Another popular way to express variation in
effect sizes is the CI, for example, the 95% CI. The CI in
a random-effects model contains highly probable values
for the summary treatment effect. However, it does not
convey what range of treatment effects are likely to be
seen in other patients, for example, in the next study or
in the patients a clinician wants to treat in her clinic.
Prediction intervals
Not so often reported but much more insightful is the
prediction interval.10 A prediction interval always pre-
sents the heterogeneity on the same scale as the original
outcomes, in contrast to τ (eg, in case of ORs), τ2 or I2.
A 95% prediction interval estimates where the true
effects are to be expected for 95% of similar (exchange-
able) studies that might be conducted in the future.4
Therefore, it is well suited to evaluate the variability of
the effect of an intervention over different settings. For
example, in a meta-analysis on sedentary time in adults
and the association with diabetes, cardiovascular disease
and death, CIs were thought to represent insufﬁciently
the different study populations. Therefore, also predic-
tion intervals were reported.11 In the absence of
between-study heterogeneity, the prediction interval
coincides with the respective CI. However, in case of het-
erogeneity, a prediction interval covers a wider range
than a CI. Consequently, in case of a statistically signiﬁ-
cant effect (where all values of the 95% CI are on the
same side of the null), the corresponding 95% predic-
tion interval may indicate that values are possible on
both sides of the null. This means that there will be set-
tings where conclusions based on CIs will not hold. In
the same framework, one can also calculate the prob-
ability that the true effect will be harmful (on the other
side of the null) in a next study. Table 1 presents an
overview of measures of between-study heterogeneity.
Example: topical steroids for nasal polyps
A 2012 review on the use of topical steroids for treat-
ment of chronic rhinosinusitis with nasal polyps, based
on seven randomised studies, resulted in a larger
decrease in overall symptom scores in favour of steroids
compared with placebo.12 This is reﬂected by a standar-
dised mean difference (SMD) of −0.51, with a 95% CI
−0.96 to −0.07 (ﬁgure 1). The I2 is 73.9% (95% CI
44.2% to 87.8%), which can be considered substantial
heterogeneity,13 and the estimated τ2 is 0.148.
Notwithstanding these numbers, it is difﬁcult to evaluate
what the clinical consequences of this heterogeneity may
be for future settings.
In order to estimate the prediction interval for the SMD,
we need the point estimate of the SMD, its SE and the esti-
mated τ2. We derive the SE from the 95% CI of the SMD
(see online supplementary appendix formula 1), which
results in an SE of 0.227. We can calculate the SD of the
prediction interval SDPI as √(0.148+0.2272) and the
lower and upper limit of the 95% prediction interval
as −0.51±2.45×SDPI. The value 2.45 results from the
t1−0.05/2,6 distribution. Prediction intervals with a differ-
ent coverage could be calculated by using a different
t-value, for example, t1−0.20/2,6 for an 80% prediction
interval (see online supplementary appendix formula 1).
The resulting prediction interval, ranging from −1.60
to 0.58, can be interpreted as the 95% range of true
SMDs to be expected in similar studies. We present it in
ﬁgure 1 as a rectangle below the diamond for the 95%
CI.14 The prediction interval contains values below zero,
which correspond to a decrease in symptom scores of at
best ∼1.6 SD after steroid use compared with placebo.
But it also contains values above zero which means that
the steroids may exhibit no or even a harmful effect
(SMD>0) in some settings, with a (95%) worst case
increase in SMD of 0.58. Consequently, the effect in a
new study may be even the exact opposite to the
summary point estimate of the meta-analysis, that is, an
increase of 0.51 instead of a decrease of −0.51 may
occur. The estimated probability that the true effect of
the steroids will be null or higher in a new study is equal
to 14.7%, based on the t-distribution with 6 degrees of
freedom (see online supplementary appendix formula 2).
Cochrane database
In order to investigate how often there is a discrepancy
in conclusions based on prediction intervals and CIs, we
evaluated this in statistically signiﬁcant meta-analyses
(p<0.05 by random-effects calculations) of the Cochrane
Database of Systematic Reviews Issues 2009–2013, kindly
provided by the UK Cochrane Editorial Unit. To avoid
subjectivity in the selection, we used the ﬁrst meta-analysis
with a dichotomous or continuous outcome and based
on at least two studies in the data and analyses section
when these studies were also combined in the original
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review, as we wanted to reﬂect the status quo as precise as
possible. Details can be found in another paper.15 In
brief, of a total of 3263 meta-analyses, 920 were statistically
signiﬁcant: 479 with an estimated I2>0 and 441 with an
estimated I2=0.
Calculations
We used the Hartung-Knapp/Sidik-Jonkman16 (HKSJ)
random-effects meta-analysis approach combined with
the empirical Bayes estimator for τ2. We estimated τ2 for
all meta-analyses, even when the authors originally per-
formed a ﬁxed-effects analysis. Prediction intervals were
calculated according to online supplementary appendix
formula 1). We categorised the statistically signiﬁcant
meta-analyses with heterogeneity (τ2>0) by number of
studies (2–6 studies or >6) and heterogeneity (I2<30%,
30% to 60% or >60%, based on the Cochrane
Handbook13 stating that an I2 between 30% and 60%
corresponds to moderate heterogeneity). For signiﬁcant
meta-analyses where the heterogeneity estimate was zero,
we assessed the impact of possibly low but non-zero het-
erogeneity by assuming an I2 of 20%, calculating predic-
tion intervals using online supplementary appendix
formula 3). Categorical outcomes were compared
between groups by means of the χ2 test. We used R soft-
ware(R: A language and environment for statistical com-
puting. Retrieved from http://www.R-project.org/.
[program]. Vienna, Austria: R Foundation for Statistical
Computing, 2014) V.3.1.2 and the R packages metafor17
V.1.9-5 and meta (meta: General Package for
Meta-Analysis. R package version 4.1-0. http://CRAN.
R-project.org/package=meta [program], 2015)V.4.1-0.
RESULTS
Overall, 132 (27.6%) of the 479 statistically signiﬁcant
meta-analyses with an I2>0 had both the 95% CI and
the 95% prediction interval excluding the null effect
(table 2). Consequently, almost three-quarter (347,
72.4%) had a prediction interval that contained the null
effect. This means that it is likely that for these compari-
sons, some patient populations might experience null
effects or effects in the opposite direction, that is, a
treatment might be more harmful than the comparator
even though the point estimate suggests beneﬁt (or vice
versa). Not surprisingly, signiﬁcant meta-analyses with
low heterogeneity more often had prediction intervals
that excluded the null than meta-analyses with high
Table 1 Some frequently used measures for heterogeneity
Measure Advantages Disadvantages
τ2 ▸ The τ (the square root of τ2) is the SD of the
between-study variation on the scale of the original
outcome.
▸ The τ2 is the direct estimate of the between-study
variation and therefore useful in calculations, for
example, for the prediction interval.
▸ A direct clinical interpretation based on τ2 is
difficult, especially when τ2 belongs to outcomes
that were analysed on log scale, for example,
ORs.
▸ When the τ2 estimate is based on only a few
studies, it will be imprecise.
I2 ▸ I2 presents the inconsistency between the study
results and quantifies the proportion of observed
dispersion that is real, that is, due to between-study
differences and not due to random error.2 3
▸ I2 reflects the extent of overlap of the CIs of the
study effects.
▸ I2 represents the inconsistency always on a scale
between 0 and 100, therefore it can be compared
with suggested limits for low or high
inconsistency.13
▸ A direct clinical interpretation of I2 is difficult.
▸ I2 is also ambiguous because its size depends on
sample size:
– With very large studies, even tiny between-study
differences in effect size may result in a high I2;
– With small (imprecise) studies, very different
treatment effects can yield an I2 of 0.
CI ▸ The CI in a random-effects model contains highly
probable values for the summary (mean) treatment
effect.
▸ The CI gives no information on the range of true
treatment effects that are likely to be seen in other
settings, for example, in the next study or in the
patients a clinician wants to treat in her clinic.
Prediction
interval
▸ The prediction interval in a random-effects model
contains highly probable values for the true
treatment effects in future settings, if those settings
are similar to the settings in the meta-analysis.
▸ The values in the interval can be compared with
clinically relevant thresholds to see whether they
correspond to benefit, null effects or harm.
▸ The prediction interval can be used to estimate the
probability that the treatment in a future setting will
have a true-positive or true-negative effect, and to
perform better power calculations.
▸ Conclusions drawn from the prediction interval are
based on the assumption that τ2 and the study
effects are normally distributed.
▸ The estimate of the prediction interval will be
imprecise if the estimates of the summary effect
and the τ2 are imprecise, for example, if they are
based on only a few studies and if these studies
are small.
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heterogeneity. The percentage of prediction intervals
containing the null effect was slightly higher for meta-
analyses with a continuous outcome (80.4%) than for
those with a dichotomous outcome (65.8%; p<0.001), but
not signiﬁcantly different for meta-analyses based on
more than six studies (74.1%) than for those with at most
six studies (69.1%; p=0.25; web table W1).
Of the 347 meta-analyses with a prediction interval
that contained the null or opposite effect, 199 (57.3%)
had also at least one study with an opposite effect. This
happened more often in meta-analyses with more than
six studies (181/235, 77.0%) than in those based on at
most six studies (18/102, 17.6%). Especially in
meta-analyses with few studies and substantial heterogen-
eity, the prediction interval was wider than the range of
study outcomes. The opposite (ie, a smaller prediction
interval) occurred in meta-analyses based on many
studies and with low estimated heterogeneity. Results for
meta-analyses with dichotomous and continuous out-
comes were not notably different.
Prediction intervals containing the opposite effect
If the prediction interval just includes the null effect,
this may be less worrying than when it contains the exact
opposite effect of the pooled summary effect, for
example, if it contains an OR of 0.5 when the
meta-analysis summary estimate is an OR of 2, or if it
contains an SMD of −0.7 when the summary estimate was
0.7. Of the 479 signiﬁcant meta-analyses with an
I2>0,97 (20.3%) had a prediction interval that contained
the opposite effect. This percentage was higher for the
meta-analyses with a continuous outcome (65/219,
29.7%) than for those with a dichotomous outcome (32/
260, 12.3%; p<0.001). It occurred also more frequently in
meta-analyses with more than six primary studies (57/
139, 41.0% and 30/178, 20.3% for meta-analyses with a
continuous or dichotomous outcome, respectively) than
for those based on at most six studies (8/80, 10.0% and
2/82, 2.4%; p<0.001 and p=0.001, respectively).
Meta-analyses with estimated I2=0
A substantial part of meta-analyses have an estimated I2
of 0. However, there is typically very large uncertainty
about the exact amount of heterogeneity, and this is
demonstrated by very large 95% CIs for the values of
I2.18 The same applies to τ: an estimate of 0 is often
accompanied by large uncertainty. The true I2 and τ are
unlikely to ever be exactly 0, although low values are
possible. To assess the impact of possibly low but
non-zero heterogeneity among the 441 Cochrane
meta-analyses with estimated I2=0 and statistically signiﬁ-
cant results, we imputed an I2=20% (suggestive of low
between-study heterogeneity). Under this assumption, in
329 (74.6%) of these 441 meta-analyses the 95% predic-
tion interval would span both sides of the null (table 2),
similar for meta-analyses with a dichotomous (74.7%) or
continuous (74.4%) outcome (web table W1). This is a
sensitivity analysis that is useful to perform to see
whether the inferences of a meta-analysis that seemingly
does not have detectable heterogeneity may be inﬂu-
enced by even a small amount of heterogeneity.
DISCUSSION AND OUTLOOK
In meta-analyses, a CI is inadequate for clinical decision-
making because it only summarises the average effect
for the average study. The prediction interval is more
informative as it shows the range of possible effects in
Figure 1 Forest plot of the standardised mean difference (SMD) in symptom scores in nasal polyps. Steroids versus placebo,
analysis 1.1 in Cochrane Review CD006549.12 Note that our results differ from the original analysis, as we used a
random-effects analysis with the Hartung-Knapp/Sidik-Jonkman adjustment16 and the empirical Bayes estimator for τ2.
Table 2 Proportion of statistically significant meta-analyses where both the 95% CIs and PIs excluded the null
Statistically significant meta-analyses Estimated heterogeneity I
2
I2=0* I2>0 >0 and <30% 30% to 60% >60%
N 441 479 123 150 206
Both 95% CI and 95% PI excluded null, n (%) 112 (25.4) 132 (27.6) 88 (71.5) 39 (26.0) 5 (2.4)
*When the estimated heterogeneity I2 was equal to 0, I2=20% was imputed for the calculation of the PI.
PI, prediction interval.
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relation to harm and clinical beneﬁt thresholds. While
we have focused on the situation where the separating
threshold is the null, a different threshold may be con-
sidered. For example, in the prediction interval frame-
work, one can calculate the probability that an effect is
larger than B, where B may be a clinically meaningful
effect (if the treatment beneﬁt is less than B, then it is
felt not to be worth it). A narrow prediction interval that
lies completely on the beneﬁcial side of a clinically rele-
vant threshold increases conﬁdence in an intervention.
A broad prediction interval may indicate the existence
of settings where the treatment has a suboptimal and
possibly even harmful effect. In more than 70% of statis-
tically signiﬁcant meta-analyses of the Cochrane
Database with some estimated or assumed between-study
heterogeneity, the prediction intervals crossed the
no-effect threshold, indicating that there are settings
where those treatments will have no effect or even an
effect in the opposite direction. In 20.3% of those
meta-analyses, the prediction interval even contained
the opposite effect of the summary estimate, for
example, an OR of 0.5 when the summary point esti-
mate was an OR of 2. This occurred most frequently for
meta-analyses with a continuous outcome, probably
because heterogeneity can be more prominent in many
topics where outcomes are assessed on continuous
scales; higher heterogeneity for the continuous out-
comes was also observed in the full set of 3263
meta-analyses.15 It was also slightly more common for
meta-analyses based on more than six studies, probably
because such meta-analyses have more power to detect
smaller effects, which means that also the opposite
effects will be smaller.
Graham and Moran19 evaluated prediction intervals in
72 meta-analyses with a dichotomous outcome in critical
care published between 2002 and 2010. They found a
higher percentage of signiﬁcant meta-analyses (50/72,
69.4%), compared with 28.5% (572/2009) in our set of
meta-analyses with an OR outcome. The difference may
be caused by publication bias, the higher number of
primary studies in their sample (median 9 vs 4 in our
set15) and by their use of the DerSimonian-Laird
approach which can result in too many statistically sig-
niﬁcant ﬁndings, whereas we used the HKSJ approach.16
However, results with respect to the prediction interval
were remarkably similar. In 32 (64.0%) of their 50 sig-
niﬁcant meta-analyses, the 95% prediction interval
included the null, similar to 65.8% in our data set.
Seven (14.0%) of their 50 meta-analyses suggested a
high probability of exact reversal of the efﬁcacy or harm,
similar to 12.3% of our meta-analyses where the predic-
tion interval contained the opposite effect, despite the
fact that they used a different deﬁnition for possible
‘harm’ and that they did not mention whether there was
positive between-study heterogeneity in their signiﬁcant
meta-analyses.
It is straightforward to calculate a prediction interval if
we can assume that the effects are normally distributed
and that τ2 is known and stable across studies. However,
one should realise that the prediction interval is depend-
ent on this assumption and on the precisions of the esti-
mated τ2 and study effect, and will be imprecise if the
number of studies in the meta-analysis is small. If the
number of studies is large, estimates will be more
precise and the normality of the distribution of τ2 can
be empirically evaluated. A ﬁnal caveat is that the uncer-
tainty conveyed by the prediction interval pertains to the
uncertainty about the extent to which future studies are
similar (exchangeable) to those that have already been
done, but this applies to all inferences from a
meta-analysis. If the future studies evaluate patients and
settings that are entirely different from what was evalu-
ated in past studies, this exchangeability is questionable
and uncertainty may be even more prominent than what
the prediction interval conveys. In practical terms, if the
patients treated by a physician are considered to be very
different from the patients seen in all studies that have
been done in the past, even the prediction interval
cannot tell us what we might expect for these patients.
Power calculations for a future study
Meta-analysis results can also be used for power calcula-
tions for a new study. However, the expected true effect
in a new study is not necessarily equal to the point esti-
mate of the meta-analysis: it can be any of the values in
the prediction interval. In case of heterogeneity, the
probability of a statistically signiﬁcant result in a new
study may differ substantially from an apparent power of
80% based on the point estimate. The latter will be
overly optimistic because the power function is asymmet-
ric. If the true study effect is larger than the point esti-
mate, the real probability of a signiﬁcant study will be
higher, up to a maximum of 100%, but if the effect is
smaller, the probability may decrease substantially, even
to 5% or less in case of a null effect. Consequently the
expected probability of a signiﬁcant new study in case of
heterogeneity will be lower than 80% ( online supple-
mentary appendix formula 4). For example, if the pre-
diction interval shows that 30% of future studies may
have a true null or negative effect, the probability of a
signiﬁcant new study can never be much larger than
70%. The sample size should be increased to compen-
sate for this loss, see also Roloff et al.20
Summarising, the prediction interval reﬂects the vari-
ation in true treatment effects over different settings,
including what effect is to be expected in future
patients, such as the patients that a clinician is interested
to treat. Therefore, it should be routinely reported in
addition to the summary effect and its CI, and used as a
main tool for interpreting evidence, to enable more
informed clinical decision-making.
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